Announcing a new publication for Acta Materia Medica journal. Treatment of cancer can be challenging, because of the disease's intricate and varied nature. Consequently, developing nanomedicines with ...
Microscopy image of invasive breast cancer cells (labelled in yellow) degrading their underlying extracellular matrix (labelled gelatin in red, degraded areas appear as black holes). Scale bar, 20µm.
Endocrine treatments for patients with hormone-sensitive breast cancer are associated with significant side effects that can negatively affect health-related quality of life and result in treatment ...
In the dynamic field of oncology, the quest for precise biomarkers to predict cancer risk, prognosis, and treatment response is paramount. These insights directly inform personalized therapeutic ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
The FDA and European Medicines Agency (EMA) have awarded orphan drug designation to CPI-008 (cRGD-ZW800-1), a novel integrin-targeted, zwitterionic imaging agent, for margin detection of pancreatic ...
MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced completion of patient enrollment in the company’s Phase 2, ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
This project will build and study an immersive multimodal system to represent and interact with human genome data to discover genetic mutations that cause cancer. In conducting this research we seek ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback